Hikma Pharmaceuticals PLC (LON:HIK)

Market Cap	2.75B -45.6%
Revenue (ttm)	2.49B +7.1%
Net Income	298.69M +12.0%
EPS	1.34 +12.4%
Shares Out	220.15M
PE Ratio	9.29
Forward PE	7.19
Dividend	0.63 (5.03%)
Ex-Dividend Date	Mar 19, 2026

Volume	383,039
Average Volume	1,592,217
Open	1,248.00
Previous Close	1,249.00
Day's Range	1,230.00 - 1,259.00
52-Week Range	1,231.34 - 2,184.00
Beta	0.65
RSI	22.76
Earnings Date	Feb 26, 2026

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 9,500
• Stock Exchange: London Stock Exchange
• Ticker Symbol: HIK

Financial Performance

In 2025, Hikma Pharmaceuticals's revenue was $3.35 billion, an increase of 7.10% compared to the previous year's $3.13 billion. Earnings were $402.00 million, an increase of 11.98%.

Financial numbers in USD